FDA Warning Letters

Covers major FDA compliance actions, analysis of warning letters, common pitfalls.

October 16, 2024
Takeaway -

Playful ads can attract scrutiny

October 9, 2024
Takeaway -

Well intentioned marketing claims can turn products into high-risk regulatory categories

October 2, 2024
Takeaway -

Learn from other’s mistakes

September 25, 2024
Takeaway -

When will FDA go after “Nature’s Ozempic” claims

September 18, 2024
Takeaway -

Do not over-explain clinical research

September 11, 2024
Takeaway -

Blogs are “labeling”

September 4, 2024
Takeaway -

Disease claims trigger deeper FDA review

August 28, 2024
Takeaway -

Cosmetics are not "FDA-approved"

August 21, 2024
Takeaway -

Even lower risk statements can trigger NAD scrutiny

August 14, 2024
Takeaway -

Copackers & distributors must comply with GMPs

August 7, 2024
Takeaway -

Flu & virus claims are enough for regulatory action

July 31, 2024
Takeaway -

Specifications continue to be cited